Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.

Steven Brad Maron,Walid K. Chatila,Brittanie M Millang,Shalom Sabwa,Joanne F. Chou,Lilan Ling,Rebecca Nagy,Marc Simmons,Richard K. G. Do,Viktoriya Paroder,Hans Gerdes,Pari Shah,Geoffrey Y. Ku,David H. Ilson,Marinela Capanu,Jaclyn F. Hechtman,Taha Merghoub,David B. Solit,Nikolaus Schultz,Yelena Y. Janjigian

Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.

2020

4559Background: Pembrolizumab can be safely combined with trastuzumab and chemotherapy and has promising activity with median OS 27 months and 91% objective response rate in HER2-positive mEG cance...

Keywords:

esophagogastric cancer
Trastuzumab
Oncology
Chemotherapy
Internal medicine
Biomarker Analysis
Pathology
Pembrolizumab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations